HSANZ Free Communications 3: CLL / basic science lymphoid malignancy
Tracks
HSANZ
| Monday, October 19, 2026 |
| 8:30 AM - 10:00 AM |
Speaker
Prof Stephen Opat
Clinical Professor
Monash Health
Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 years) treatment-naïve CLL/SLL patients, including those with del(17p): subgroup analysis from the SEQUOIA trial
8:30 AM - 8:45 AM
Stephen S. Opat
First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53
8:45 AM - 9:00 AM
Dr Joshua W.D. Tobin
BCR neoantigens drive T-cell immunity and favourable outcomes in Chronic Lymphocytic Leukaemia
9:00 AM - 9:15 AM
Dr Eric Wenlong Li
Phd Candidate
Walter and Eliza Hall Institute of Medical Research
MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF‑κB in mature B-cell malignancies
9:15 AM - 9:30 AM
Mr Dion Marinkovich
Sr Advisor – Medical Affairs
Eli Lilly and Company
Pirtobrutinib in post-cBTKi chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): phase 1/2 BRUIN study with more than 5 years follow-Up (final update)
9:30 AM - 9:45 AM
Prof Judith Trotman
Hematologist
Concord Repatriation General Hospital, University Of Sydney
BGB-16673, a Bruton tyrosine kinase degrader, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the CaDAnCe-101 study
9:45 AM - 10:00 AM
